Search | Clinical Trials Finder

Conditions: Obesity
Interventions: maridebart cafraglutide, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Anaheim, California • Tustin, California • Miami, Florida

Conditions: HCV Infection
Interventions: VCH 916, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Advanced HER2+Breast Cancer
Interventions: Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Los Angeles, California

Conditions: Psoriasis
Interventions: Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more

Conditions: Healthy Participants
Interventions: AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Aging Frailty
Interventions: Longeveron Mesenchymal Stem Cells (LMSCs), Fluzone High Dose Vaccine; Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 6
States / cities: Coral Gables, Florida • Fort Myers, Florida • Miami, Florida + 2 more

Conditions: Dengue
Interventions: ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo; Drug · Other
Lead sponsor: Island Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Healthy Volunteer
Interventions: BIIB142, BIIB142-Matching Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Obesity, Overweight, Healthy
Interventions: PF-04620110, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Rheumatoid Arthritis
Interventions: TCK-276, TCK-276 Placebo; Drug
Lead sponsor: Teijin America, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Tustin, California • Doral, Florida • Miami, Florida + 3 more

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort C: bevacizumab, Cohort C: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Cognitive Dysfunction, Schizophrenia
Interventions: KYN-5356, placebo; Drug
Lead sponsor: Kynexis B.V.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Alcohol Use Disorder
Interventions: CMND-100; Drug
Lead sponsor: Clearmind Medicine Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: FB704A, Placebo; Drug
Lead sponsor: Fountain Biopharma Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Geographic Atrophy, Age-Related Macular Degeneration
Interventions: Emixustat HCl Tablet, Placebo Tablet; Drug · Other
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes Mellitus
Interventions: DS-7309, placebo, Metformin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bacterial Infections
Interventions: TP-271; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants, Obesity
Interventions: AZD1043, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
Interventions: Placebo, Lemborexant 10 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 11
States / cities: Glendale, Arizona • San Diego, California • Brandon, Florida + 7 more

Conditions: Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
Interventions: RSV preF-based Vaccine, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more

Conditions: Hepatitis C
Interventions: 200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Ventral Hernia, Abdominal Hernia
Interventions: BOTOX Dose A, Placebo for BOTOX, BOTOX Dose B, BOTOX Dose C; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Mineola, New York • Charlotte, North Carolina

Conditions: Healthy
Interventions: LY3410738, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Daytona Beach, Florida • Madison, Wisconsin

Search by objective public record fields.

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

Study to Examine the Effects of Oral Fenretinide

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

A Study of LY3410738 in Healthy Adult Participants